ep rais encourag ajovi sign
encourag earli sign ajovi launch teva stock under-perform
past month head earn made
loss follow morn print signific beat rais quarter
teva beat consensu ep rais ep guidanc
midpoint along manag commentari continu
sign gener stabil progress restructur plan
ralli also driven part posit sign initi ajovi launch
normal prescript trend line seen aimovig
point launch prescript date written
ajovi quarterli dose suggest dose could provid real differenti
competit class current model sale ajovi
wait see payer accept new class drug
rais estim given signific beat quarter rais
ep note potenti upward
revis particularli copaxon continu hold better expect
chang ep
put estim line manag commentari
return growth year bottom line
maintain target price neutral rate quarterli perform
continu deliveri target provid need stabil
teva stori continu posit traction ajovi austedo could
increas enthusiasm stock see overal
risk/reward fairli balanc tp base ev/ebitda
multipl ebitda risk view teva
includ better-/worse-than expect execut restructur plan gener
approv ajovy/austedo launch
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
teva israel-bas pharmaceut compani focus primarili
research develop commerci gener
specialti drug two oper segment gener medicin
specialti medicin
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat driven larg part effici
optim gener busi slower anticip
eros copaxon sale launch new product
compani debt situat resolv effici
grey sky valuat driven larg part bearish
assumpt around sale copaxon gener
busi us need renogoti debt
 close
takeaway convers manag
key potenti gener launch us includ
epipen launch expect impact continu
forteo lilli comment gener competit expect
part teva strategi
invest manufactur facil germani
near-term focu asset celltrion lot earlier stage research littl
earli speak
biosimilar rituxan disclos actual launch date agre settlement
roch model base commentari roch
saw posit benefit gross-to-net adjust over-accru
manag expect step-down factor guidanc
market rel stabl
posit price adjust neg impact yoy growth
teva expect proair gener probabl mayb
expect impact wholesal stock connect qvar redihal
launch larg
expect qvar sale return per quarter rang inventori
due geograph mix sale
copaxon fade tax rate increas
expect move rang time progress
us million except per share valu
sale
sale
sale
sale
us million unless otherwis state
share
us million unless otherwis state
us million unless otherwis state
fremanezumab anti-cgrp migrain
fremanezumab anti-cgrp migrain
us million unless otherwis state
sale
incom invest
incom incom tax
share loss associ compani net
net incom non-control interest
net gain loss attribut non-control interest
dividend prefer share
weight average share use calcul dilut ep
compani mention price
